Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. As the creator of the blockbuster weight-loss drug Zepbound, and ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Scientists recently studied how different factors affect antisense oligonucleotides (ASOs) under hydrophilic interaction ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli ... about Lilly's capacity buildup. I think it's a key one ...